10:20 AM EST - Oncolytics Biotech Inc : Announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab in patients with =2L metastatic SCAC. Patients from this cohort continue to be followed, and additional efficacy data are expected to be reported. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.06 at $1.27.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7689006863922289
